Your browser doesn't support javascript.
loading
Functional and pharmacological role of the dopamine D4 receptor and its polymorphic variants.
Ferré, Sergi; Belcher, Annabelle M; Bonaventura, Jordi; Quiroz, César; Sánchez-Soto, Marta; Casadó-Anguera, Verònica; Cai, Ning-Sheng; Moreno, Estefanía; Boateng, Comfort A; Keck, Thomas M; Florán, Benjamín; Earley, Christopher J; Ciruela, Francisco; Casadó, Vicent; Rubinstein, Marcelo; Volkow, Nora D.
Affiliation
  • Ferré S; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes on Drug Abuse, Baltimore, MD, United States.
  • Belcher AM; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Bonaventura J; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes on Drug Abuse, Baltimore, MD, United States.
  • Quiroz C; Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, Spain.
  • Sánchez-Soto M; Neuropharmacology & Pain Group, Neuroscience Program, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain.
  • Casadó-Anguera V; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes on Drug Abuse, Baltimore, MD, United States.
  • Cai NS; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes on Drug Abuse, Baltimore, MD, United States.
  • Moreno E; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
  • Boateng CA; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes on Drug Abuse, Baltimore, MD, United States.
  • Keck TM; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
  • Florán B; Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point, NC, United States.
  • Earley CJ; Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ, United States.
  • Ciruela F; Departament of Physiology, Biophysics and Neurosciences, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.
  • Casadó V; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
  • Rubinstein M; Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, Spain.
  • Volkow ND; Neuropharmacology & Pain Group, Neuroscience Program, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain.
Front Endocrinol (Lausanne) ; 13: 1014678, 2022.
Article in En | MEDLINE | ID: mdl-36267569
ABSTRACT
The functional and pharmacological significance of the dopamine D4 receptor (D4R) has remained the least well understood of all the dopamine receptor subtypes. Even more enigmatic has been the role of the very prevalent human DRD4 gene polymorphisms in the region that encodes the third intracellular loop of the receptor. The most common polymorphisms encode a D4R with 4 or 7 repeats of a proline-rich sequence of 16 amino acids (D4.4R and D4.7R). DRD4 polymorphisms have been associated with individual differences linked to impulse control-related neuropsychiatric disorders, with the most consistent associations established between the gene encoding D4.7R and attention-deficit hyperactivity disorder (ADHD) and substance use disorders. The function of D4R and its polymorphic variants is being revealed by addressing the role of receptor heteromerization and the relatively avidity of norepinephrine for D4R. We review the evidence conveying a significant and differential role of D4.4R and D4.7R in the dopaminergic and noradrenergic modulation of the frontal cortico-striatal pyramidal neuron, with implications for the moderation of constructs of impulsivity as personality traits. This differential role depends on their ability to confer different properties to adrenergic α2A receptor (α2AR)-D4R heteromers and dopamine D2 receptor (D2R)-D4R heteromers, preferentially localized in the perisomatic region of the frontal cortical pyramidal neuron and its striatal terminals, respectively. We also review the evidence to support the D4R as a therapeutic target for ADHD and other impulse-control disorders, as well as for restless legs syndrome.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dopamine / Receptors, Dopamine D4 Limits: Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dopamine / Receptors, Dopamine D4 Limits: Humans Language: En Journal: Front Endocrinol (Lausanne) Year: 2022 Document type: Article Affiliation country: